Hepatitis B virus: Old, new and future approaches to antiviral treatment

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 4, 2003, Pages 761-785

  Karayiannis, Peter ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antivirals; HBV

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; APTAMER; BETA INTERFERON; CLEVUDINE; DNA VACCINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; FIALURIDINE; FLUCYTOSINE DEOXYRIBOSIDE; GAMMA INTERFERON; GANCICLOVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; LAMIVUDINE; NUCLEOSIDE ANALOG; PARACETAMOL; PENCICLOVIR; PREDNISOLONE; RIBOZYME; TENOFOVIR DISOPROXIL; THYMOSIN; UNINDEXED DRUG; VIRUS DNA;

AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIBIOTIC SENSITIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; FATIGUE; FLU LIKE SYNDROME; GENE THERAPY; HAIR LOSS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IRRITABILITY; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER HISTOLOGY; LONG TERM CARE; MONOTHERAPY; MOOD DISORDER; NONHUMAN; REVIEW; SEROCONVERSION; TREATMENT OUTCOME; VACCINATION; VIRUS MUTANT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOTHERAPY; INTERFERONS; MOLECULAR BIOLOGY; NUCLEOSIDES;

EID: 0037394275     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg163     Document Type: Review

References (300)

1. Lee, W. M. (1997). Hepatitis B virus infection. New England Journal of Medicine 337, 1733-45.
2. 1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody- and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 24, 774-7.
3. 1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 27, 1383-7.
4. Michel, M. L., Pol, S., Brechot, C. & Tiollais, P. (2001). Immunotherapy of chronic hepatitis B by anti-HBV vaccine: from present to future. Vaccine 19, 2395-9.
5. Schäfer, S., Tolle, T., Lottmann, S. & Gerlich, W. H. (1998). Animal models and experimental systems in hepatitis B virus research. In Hepatitis B Virus: Molecular Mechanisms in Disease and Novel Strategies for Therapy (Koshy, R. C. & Caselmann, W. H., Eds), pp. 51-74. Imperial College Press, London, UK.
6. Schödel, F., Weimer, T., Fernholz, D., Schneider, R., Sprengel, R., Wildner, G. et al. (1991). The biology of avian hepatitis B viruses. In Molecular Biology of Hepatitis B Viruses (McLachlan, A., Ed.), pp. 53-80. CRC Press, Boca Raton, FL, USA.
7. Triyatni, M., Ey, P., Tran, T., Le Mire, M., Qiao, M., Burrell, C. et al. (2000). Sequence comparison of an Australian duck hepatitis B virus strain with other avian hepadnaviruses. Journal of General Virology 82, 373-8.
8. Seeger, C. & Mason, W. S. (2000). Hepatitis B virus biology. Microbiology and Molecular Biology Reviews 64, 51-68.
9. Ganem, D. & Schneider, R. J. (2001). Hepadnaviridae: the viruses and their replication. In Fields Virology, 4th edn (Knipe, D. M., Griffin, D. E., Lamb, R. A., Martin, M. A., Roizman, B. & Straus, S. E., Eds), pp. 2923-69. Lippincott Williams & Wilkins, Philadelphia, PA, USA.
10. Neurath, A. R., Kent, S. B., Strick, N. & Parker, K. (1986). Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46, 429-36.
11. Neurath, A. R., Seto, B. & Strick, N. (1989). Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective. Vaccine 7, 234-6.
12. Paran, N., Geiger, B. & Shaul, Y. (2001). HBV infection of cell culture: evidence for multivalent and cooperative attachment. EMBO Journal 20, 4443-53.
13. Tuttleman, J. S., Pourcel, C. & Summers, J. (1986). Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47, 451-60.
14. Locarnini, S. & Birch, C. (1999). Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. Journal of Hepatology 30, 536-50.
15. Nowak, M. A., Bonhoeffer, S., Hill, A. M., Boehme, R., Thomas, H. C. & McDade, H. (1996). Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences, USA 93, 4398-402.
16. Zeuzem, S., de Man, R. A., Honkoop, P., Roth, W. K., Schalm, S. W. & Schmidt, J. M. (1997). Dynamics of hepatitis B virus infection in vivo. Journal of Hepatology 27, 431-6.
17. Lewin, S., Walters, T. & Locarnini, S. (2002). Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. Antiviral Research 55, 381-96.
18. Summers, J. & Mason, W. S. (1982). Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29, 403-15.
19. Kramvis, A. & Kew, M. C. (1998). Structure and function of the encapsidation signal of hepadnaviridae. Journal of Viral Hepatitis 5, 357-67.
20. Nassal, M. & Schaller, H. (1996). Hepatitis B virus replication - an update. Journal of Viral Hepatitis 3, 217-26.
21. Zoulim, F. & Seeger, C. (1994). Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. Journal of Virology 68, 6-13.
22. Weber, M., Bronsema, V., Bartos, H., Bosserhoff, A., Bartenschlager, R. & Schaller, H. (1994). Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription. Journal of Virology 68, 2994-9.
23. Crowther, R. A., Kiselev, N. A., Bottcher, B., Berriman, J. A., Borisova, G. P., Ose, V. et al. (1994). Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell 77, 943-50.
24. Gerelsaikhan, T., Tavis, J. E. & Bruss, V. (1996). Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. Journal of Virology 70, 4269-72.
25. Magnius, L. O. & Norder, H. (1995). Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 38, 24-34.
26. Yamamoto, K., Horikita, M., Tsuda, F., Itoh, K., Akahane, Y., Yotsumoto, S. et al. (1994). Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. Journal of Virology 68, 2671-6.
27. Mimms, L. (1995). Hepatitis B virus escape mutants: 'pushing the envelope' of chronic hepatitis B virus infection. Hepatology 21, 884-7.
28. Carman, W. F., Zanetti, A. R., Karayiannis, P., Waters, J., Manzillo, G., Tanzi, E. et al. (1990). Vaccine-induced escape mutant of hepatitis B virus. Lancet 336, 325-9.
29. Carman, W. F., Jacyna, M. R., Hadziyannis, S., Karayiannis, P., McGarvey, M. J., Makris, A. et al. (1989). Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2, 588-91.
30. Brunetto, M. R., Stemler, M., Schodel, F., Will, H., Ottobrelli, A., Rizzetto, M. et al. (1989). Identification of HBV mutants which cannot produce pre-core derived HBeAg and may be responsible for severe hepatitis. Italian Journal of Gastroenterology 2, 151-4.
31. Okamoto, H., Tsuda, F., Akahane, Y., Sugai, Y., Yoshiba, M., Moriyama, K. et al. (1994). Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. Journal of Virology 68, 8102-10.
32. Hadziyannis, S. (1995). Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Reviews 1, 7-36.
33. Scaglioni, P. P., Melegari, M. & Wands, J. R. (1997). Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 233, 374-81.
34. Lindh, M., Andersson, A. S. & Gusdal, A. (1997). Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus - large-scale analysis using a new genotyping method. Journal of Infectious Diseases 175, 1285-93.
35. Buckwold, V. E., Xu, Z., Chen, M., Yen, T. S. & Ou, J. H. (1996). Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. Journal of Virology 70, 5845-51.
36. Karayiannis, P., Fowler, M. J. F., Lok, A. S. F., Greenfield, C., Monjardino, J. & Thomas, H. C. (1985). Detection of serum HBV-DNA by molecular hybridisation: correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. Journal of Hepatology 1, 99-106.
37. Zarski, J. P., Marcellin, P., Cohard, M., Lutz, J. M., Bouche, C. & Rais, A. (1994). Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group. Journal of Hepatology 20, 636-40.
38. Brunetto, M. R., Giarin, M. M., Oliveri, F., Chiaberge, E., Baldi, M., Alfarano, A. et al. (1991). Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proceedings of the National Academy of Sciences, USA 88, 4186-90.
39. Margolis, H. S., Alter, M. J. & Hadler, S. C. (1991). Hepatitis B: evolving epidemiology and implications for control. Seminars in Liver Disease 11, 84-92.
40. Corsaget, P., Yvonnet, B., Chotard, J., Vincelot, P., Sarr, M., Diouf, C. et al. (1987). Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). Journal of Medical Virology 22, 1-5.
41. McMahon, B. J., Alward, W. L. M., Hall, D. B., Heyward, W. L., Bender, T. R., Francis, D. P. et al. (1985). Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. Journal of Infectious Diseases 151, 599-603.
42. Tassopoulos, N. C., Papaevangelou, G. J., Sjogren, M. H., Roumeliotou-Karayannis, A., Gerin, J. L. & Purcell, R. H. (1987). Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 92, 1844-50.
43. Evans, A. A. & London, W. T. (1998). Epidemiology of hepatitis B. In Viral Hepatitis (Zuckerman, A. J. & Thoms, H. C., Eds), pp. 107-14. Churchill Livingstone, London, UK.
44. Wong, D. K., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S. & Heathcote, J. (1993). Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Annals of Internal Medicine 119, 312-23.
45. Lok, A. S., Lai, C. L., Wu, P. C. & Leung, E. K. (1988). Longterm follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 2, 298-302.
46. Lok, A. S., Wu, P. C., Lai, C. L., Lau, J. Y., Leung, E. K., Wong, L. S. et al. (1992). A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102, 2091-7.
47. Lai, C. L., Lok, A. S., Lin, H. J., Wu, P. C., Yeoh, E. K. & Yeung, C. Y. (1987). Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet 2, 877-80.
48. Lok, A. S., Lai, C. L., Wu, P. C., Lau, J. Y., Leung, E. K. & Wong, L. S. (1989). Treatment of chronic hepatitis B with interferon: experience in Asian patients. Seminars in Liver Disease 9, 249-53.
49. Perrillo, R. P. (1989). Treatment of chronic hepatitis B with interferon: experience in western countries. Seminars in Liver Disease 9, 240-8.
50. Gregorio, G. V., Jara, P., Hierro, L., Diaz, C., de la Vega, A., Vegnente, A. et al. (1996). Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 23, 700-7.
51. Sokal, E. M., Conjeevaram, H. S., Roberts, E. A., Alvarez, F., Bern, E. M., Goyens, P. et al. (1998). Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 114, 988-95.
52. Lin, S. M., Sheen, I. S., Chien, R. N., Chu, C. M. & Liaw, Y. F. (1999). Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29, 971-5.
53. Lau, D. T., Everhart, J., Kleiner, D. E., Park, Y., Vergalla, J., Schmid, P. et al. (1997). Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113, 1660-7.
54. Niederau, C., Heintges, T., Lange, S., Goldman, G., Niederau, C. M., Mohr, L. et al. (1996). Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. New England Journal of Medicine 334, 1422-7.
55. Fattovich, G., Giustina, G., Realdi, G., Corroacher, R., Schalm, S. W. & the European Concerted Action of Viral Hepatitis (EUROHEP). (1997). Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 26, 1338-42.
56. Lok, A. S., Chung, H. T., Liu, V. W. & Ma, O. C. (1993). Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 105, 1833-8.
57. Korenman, J., Baker, B., Waggoner, J., Everhart, J. E., Di Bisceglie, A. M. & Hoofnagle, J. H. (1991). Long-term remission of chronic hepatitis B after alpha-interferon therapy. Annals of Internal Medicine 114, 629-34.
58. Krogsgaard, K. (1998). The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. Journal of Viral Hepatitis 5, 389-97.
59. Lok, A. S., Heathcote, E. J. & Hoofnagle, J. H. (2001). Management of Hepatitis B 2000, Summary of a Workshop. Gastroenterology 120, 1828-53.
60. Lampertico, P., Del Ninno, E., Manzin, A., Donato, M. F., Rumi, M. G., Lunghi, G. et al. (1997). A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 26, 1621-5.
61. Fattovich, G., Farci, P., Rugge, M., Brollo, L., Mandas, A., Pontisso, P. et al. (1992). A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 15, 584-9.
62. Hadziyannis, S., Bramou, T., Makris, A., Moussoulis, G., Zignego, L. & Papaioannou, C. (1990). Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. Journal of Hepatology 11, Suppl. 1, S133-6.
63. Pastore, G., Santantonio, T., Milella, M., Monno, L., Mariano, N., Moschetta, R. et al. (1992). Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. Journal of Hepatology 14, 221-5.
64. Brunetto, M. R., Oliveri, F., Coco, B., Leandro, G., Colombatto, P., Gorin, J. M. et al. (2002). Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. Journal of Hepatology 36, 263-70.
65. Papatheodoridis, G. V., Manesis, E. & Hadziyannis, S. J. (2001). The long-term outcome of interferon-alfa treated and untreated patients with HBeAg negative chronic hepatitis B. Journal of Hepatology 34, 306-13.
66. Brunetto, M. R., Oliveri, F., Demartini, A., Calvo, P., Manzini, P., Cerenzia, M. T. et al. (1991). Treatment with interferon of chronic hepatitis B associated with antibody to hepatitis B e antigen. Journal of Hepatology 13, Suppl. 1, S8-11.
67. Erhardt, A., Reineke, U., Blondin, D., Gerlich, W. H., Adams, O., Heintges, T. et al. (2000). Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 31, 716-25.
68. Manesis, E. K. & Hadziyannis, S. J. (2001). Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121, 101-9.
69. Carreno, V., Marcellin, P., Hadziyannis, S., Salmeron, J., Diago, M., Kitis, G. E. et al. (1999). Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 30, 277-82.
70. Nevens, F., Goubau, P., Van Eyken, P., Desmyter, J., Desmet, V. & Fevery, J. (1993). Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 13, 15-9.
71. Perrillo, R., Tamburro, C., Regenstein, F., Balart, L., Bodenheimer, H., Silva, M. et al. (1995). Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 109, 908-16.
72. Marcellin, P., Giuily, N., Loriot, M. A., Durand, F., Samuel, D., Bettan, L. et al. (1997). Prolonged interferon-alpha therapy of hepatitis B virus-related decompensated cirrhosis. Journal of Viral Hepatitis 4, Suppl, 1, S21-6.
73. Tchervenkov, J. I., Tector, A. J., Barkun, J. S., Sherker, A., Forbes, C. D., Elias, N. et al. (1997). Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Annals of Surgery 226, 356-65.
74. Marcellin, P., Samuel, D., Areias, J., Loriot, M. A., Arulnaden, J.L., Gigou, M. et al. (1994). Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 19, 6-12.
75. Brook, M. G., Karayiannis, P. & Thomas, H. C. (1989). Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? Hepatology 10, 761-3.
76. Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Jr, Lindsay, K., Payne, J. et al. (1990). A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. New England Journal of Medicine 323, 295-301.
77. Nair, S. & Perrillo, R. P. (2001). Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 34, 1021-6.
78. Kao, J. H., Wu, N. H., Chen, P. J., Lai, M. Y. & Chen, D. S. (2000). Hepatitis B genotypes and the response to interferon therapy. Journal of Hepatology 33, 998-1002.
79. Cohard, M., Poynard, T., Mathurin, P. & Zarski, J. P. (1994). Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology 20, 1390-8.
80. Lok, A. S., Wu, P. C., Lai, C. L., Lau, J. Y., Leung, E. K., Wong, L. S. et al. (1992). A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102, 2091-7.
81. Krogsgaard, K., Marcellin, P., Trepo, C., Berthelot, P., Sanchez-Tapias, J. M., Bassendine, M. et al. (1996). Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. Journal of Hepatology 25, 803-13.
82. Fernandez-Soto, L., Gonzalez, A., Escobar-Jimenez, F., Vazquez, R., Ocete, E., Olea, N. et al. (1998). Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Archives of Internal Medicine 158, 1445-8.
83. Chisari, F. V. (1995). Hepatitis B virus immunopathogenesis. Annual Reviews in Immunology 13, 29-60.
84. Gerin, J. L., Korba, B. E., Cote, P. J. & Tennant, B. C. (1992). A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection. Advances in Experimental Medicine and Biology 312, 121-3
85. Mutchnick, M. G., Lindsay, K. L., Schiff, E. R., Cummings, G. D., Appelman, H. D., Peleman, R. R. et al. (1999). Thymosin alpha 1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. Journal of Viral Hepatitis 6, 397-403.
86. Chan, H. L., Tang, J. L., Tam, W. & Sung, J. J. (2001). The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Alimentary Pharmacology and Therapeutics 15, 1899-905.
87. Carreno, V., Zeuzem, S., Hopf, U., Marcellin, P., Cooksley, W. G., Fevery, J. et al. (2000). A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. Journal of Hepatology 32, 317-24.
88. Focher, F., Maga, G., Bendiscioli, A., Capobianco, M., Colonna, F., Garbesi, A. et al. (1995). Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D- and L-thymidine 5′-triphosphate as substrate. Nucleic Acids Research 23, 2840-47.
89. Krayevsky, A. A., Dyatkina, N. B., Semizarov, D. G., Victorova, L. S., Shirokova, E. A., Theil, F. et al. (1999). Reasons and limits of substrate activity of modified L-dNTP in DNA biosynthesis. Nucleosides and Nucleotides 18, 863-4.
90. Davis, M. G., Wilson, J. E., VanDraanen, N. A., Miller, W. H., Freeman, G. A., Daluge, S. M. et al. (1996). DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs. Antiviral Research 30, 133-45.
91. Moraleda, G., Saputelli, J., Aldrich, C. E., Averett, D., Condreay, L. & Mason, W. S. (1997). Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. Journal of Virology 71, 9392-9.
92. Delaney, W., Miller, T. & Isom, H. (1999). Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-[beta]-2′,3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Anti-microbial Agents and Chemotherapy 43, 2017-26.
93. Addison, W. R., Walters, K. A., Wong, W. W., Wilson, J. S., Madej, D., Jewell, L. D. et al. (2002). Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. Journal of Virology 76, 6356-63.
94. Cammack, N., Rouse, P., Marr, C. L., Reid, P. J., Boehme, R. E., Coates, J. A. et al. (1992). Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochemical Pharmacology 43, 2059-64.
95. Chang, C. N., Skalski, V., Zhou, J. H. & Cheng, Y. C. (1992). Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. Journal of Biological Chemistry 267, 22414-20.
96. Doong, S. L., Tsai, C. H., Schinazi, R. F., Liotta, D. C. & Cheng, Y. C. (1991). Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proceedings of the National Academy of Sciences, USA 88, 8495-9.
97. Tassopoulos, N. C., Volpes, R., Pastore, G., Heathcote, J., Buti, M., Goldin, R. D. et al. (1999). Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29, 889-96.
98. Lok, A. S. F., Hussain, M., Cursano, C., Margotti, M., Gramenzi, A., Grazi, G. L. et al. (2000). Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 32, 1145-53.
99. Cho, S. W., Hahm, K. B. & Kim, J. H. (2000). Reversion from precore/core promoter mutants to wild type hepatitis B virus during the course of lamivudine therapy. Hepatology 32, 1163-9.
100. Zoulim, F. & Trepo, C. (2000). Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? Hepatology 32, 1172-4.
101. Chen, R. Y., Edwards, R., Shaw, T., Colledge, D., Delaney, W. E., Isom, H. et al. (2003). Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37, 27-35.
102. Boni, C., Penna, A., Ogg, G. S., Bertoletti, A., Pilli, M., Cavallo, C. et al. (2001). Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33, 963-71.
103. Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H. W., Goodman, Z. et al. (1999). Lamivudine as initial treatment for chronic hepatitis B in the United States. New England Journal of Medicine 341, 1256-63.
104. Lai, C. L., Chien, R. N., Leung, N. W., Chang, T. T., Guan, R., Tai, D. I. et al. (1998). A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. New England Journal of Medicine 339, 61-8.
105. Schalm, S. W., Heathcote, J., Cianciara, J., Farrell, G., Sherman, M., Willems, B. et al. (2000). Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46, 562-8.
106. Liaw, Y. F., Leung, N. W. Y., Chang, T. T., Guan, R., Tai, D. I., Ng, K. Y. et al. (2000). Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119, 172-80.
107. Leung, N. W. Y., Lai, C. L., Chang, T. T., Guan, R., Lee, C. M., Ng, K. Y. et al. (2001). Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen sero-conversion rates: results after 3 years of therapy. Hepatology 33, 1527-32.
108. Chang, T. T., Lai, C. L., Liaw, Y. F., Guan, R., Lim, S. G., Lee, C. M. et al. (2000). Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years (abstract). Antiviral Therapy 5, Suppl. 1, 44.
109. Chien, R. N., Liaw, Y. F. & Atkins, M. (1999). Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 30, 770-4.
110. Perrillo, R. P., Schalm, S. W., Schiff, E. R., Brown, N. A., Woessner, M. A. & Sullivan, M. (1999). Predictors of HBsAg sero-conversion in chronic hepatitis B patients treated with lamivudine (abstract). Hepatology 30, 317A.
111. Jonas, M. M., Kelly, D. A., Mizerski, J., Badia, I. B., Areias, J. A., Schwarz, K. B. et al. (2002). International Pediatric Lamivudine Investigator Group Clinical trial of lamivudine in children with chronic hepatitis B. New England Journal of Medicine 346, 1706-13.
112. Rizzetto, M. (2002). Efficacy of lamivudine in HBeAg-negative chronic hepatitis B. Journal of Medical Virology 66, 435-51.
113. Santantonio, T., Mazzola, M., Iacovazzi, T., Miglietta, A., Guastadisegni, A. & Pastore, G. (2000). Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. Journal of Hepatology 32, 300-6.
114. Hadziyannis, S. J., Papatheodoridis, G. V., Dimou, E., Laras, A. & Papaioannou, C. (2000). Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32, 847-51.
115. Lau, D. T., Khokhar, M. F., Doo, E., Ghany, M. G., Herion, D., Park, Y. et al. (2000). Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32, 828-34.
116. Rizzetto, M., Volpes, R. & Smedile, A. (2000). Response of pre-core mutant chronic hepatitis B infection to lamivudine. Journal of Medical Virology 61, 398-400.
117. Papatheodoridis, G. V., Dimou, E., Laras, A., Papadimitropoulos, V. & Hadziyannis, S. J. (2002). Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 36, 219-26.
118. Scotto, G., Fazio, V., Campanozzi, F. & D'Adduzio, A. (2000). Efficacy of treatment with lamivudine in patients with chronic active E-minus variant hepatitis B virus infection: a non-randomized, open label study. Current Therapeutic Research 61, 321-30.
119. Suzuki, Y., Kumada, H., Ikeda, K., Chayama, K., Arase, Y., Saitoh, S. et al. (1999). Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. Journal of Hepatology 30, 743-8.
120. Kweon, Y. O., Goodman, Z. D., Dienstag, J. L., Schiff, E. R., Brown, N. A., Burkhardt, E. et al. (2001). Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. Journal of Hepatology 35, 749-55.
121. Tsubota, A., Arase, Y., Saitoh, S., Kobayashi, M., Suzuki, Y., Suzuki, F. et al. (2001). Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study. American Journal of Gastroenterology 96, 557-62.
122. Buti, M., Cotrina, M., Jardi, R., de Castro, E. C., Rodriguez-Frias, F., Sanchez-Avila, F. et al. (2001). Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. Journal of Viral Hepatitis 8, 270-5.
123. Perrillo, R. P., Wright, T., Rakela, J., Levy, G., Schiff, E., Gish, R. et al. (2001). A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33, 424-32.
124. Villeneuve, J. P., Condreay, L. D., Willems, B., Pomier-Layrargues, G., Fenyves, D., Bilodeau, M. et al. (2000). Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31, 207-10.
125. Yao, F. Y. & Bass, N. M. (2000). Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. Journal of Hepatology 33, 301-7.
126. Kapoor, D., Guptan, R. C., Wakil, S. M., Kazim, S. N., Kaul, R., Agarwal, S. R. et al. (2000). Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. Journal of Hepatology 33, 308-12.
127. Bain, V. G., Kneteman, N. M., Ma, M. M., Gutfreund, K., Shapiro, J. A., Fischer, K. et al. (1996). Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62, 1456-62.
128. Grellier, L., Mutimer, D., Ahmed, M., Brown, D., Burroughs, A., Rolles, K. et al. (1996). Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348, 1212-5.
129. Herrero, J. I., Quiroga, J., Sangro, B., Sola, I., Riezu-Boj, J. I., Pardo, F. et al. (1998). Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation. Digestive Diseases and Sciences 43, 1186-9.
130. Nery, J. R., Weppler, D., Rodriguez, M., Ruiz, P., Schiff, E. R. & Tzakis, A. G. (1998). Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 65, 1615-21.
131. Honkoop, P., de Man, R. A., Zondervan, P. E. & Schalm, S. W. (1997). Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 17, 103-6.
132. Perrillo, R. P., Wright, T., Rakela, J., Levy, G., Schiff, E., Gish, R. et al. (2001). The Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33, 424-32.
133. Markowitz, J. S., Martin, P., Conrad, A. J., Markmann, J. F., Seu, P., Yersiz, H. et al. (1998). Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28, 585-9.
134. Naoumov, N. V., Lopes, A. R., Burra, P., Caccamo, L., Lemmolo, R. M., de Man, R. A. et al. (2001). Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Journal of Hepatology 34, 888-94.
135. Lo, C. M., Cheung, S. T., Lai, C. L., Liu, C. L., Ng, I. O., Yuen, M. F. et al. (2001). Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Annals of Surgery 233, 276-81.
136. Liaw, Y. F., Tsai, S. L., Chien, R. N., Yeh, C. T. & Chu, C. M. (2000). Prednisolone priming enhances Th 1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 32, 604-9.
137. Song, B. C., Suh, D. J., Lee, H. C., Chung, Y. H. & Lee, Y. S. (2000). Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32, 803-6.
138. Dienstag, J. L., Schiff, E. R., Mitchell, M., Casey, D. E., Jr, Gitlin, N., Lissoos, T. et al. (1999). Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 30, 1082-7.
139. Schiff, E., Cianciara, J., Karayalcin, S., Kowdley, K., Woesner, M., McMullen, S. et al. (2000). Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B (abstract). Journal of Hepatology 32, Suppl. 2, 99.
140. Liaw, Y. F., Chien, R. N., Yeh, C. T., Tsai, S. L. & Chu, C. M. (1999). Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30, 567-72.
141. Bartholomew, M. M., Jansen, R. W., Jeffers, L. J., Reddy, K. R., Johnson, L. C., Bunzendahl, H. et al. (1997). Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349, 20-2.
142. Atkins, M., Hunt, C. M., Brown, N., Gray, F., Sanathanan, L., Woesser, M. et al. (1998). Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients [abstract]. Hepatology 28, 319A.
143. Hsiou, Y., Ding, J., Das, K., Clark, A. D., Hughes, S. H. & Arnold, E. (1996). Structure of unliganded HIV-1 reverse transcriptase at 2.7 angstrom resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4, 853-60.
144. Lavrik, O. I., Prasad, R., Beard, W. A., Safronov, I. V., Dobrikov, M. I., Srivastava, D. K. et al. (1996). dNTP binding to HIV-1 reverse transcriptase and mammalian DNA polymerase beta as revealed by affinity labeling with a photoreactive dNTP analog. Journal of Biological Chemistry 271, 21891-7.
145. Sarafianos, S. G., Das, K., Clark, A. D., Ding, J., Boyer, P. L., Hughes, S. H. et al. (1999). Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proceedings of the National Academy of Sciences, USA 96, 10027-32.
146. Gao, H.-Q., Boyer, P.L., Sarafianos, S. G., Arnold, E. & Hughes, S. H. (2000). The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. Journal of Biological Chemistry 300, 403-18.
147. Poch, O., Sauvaget, I., Delarue, M. & Tordo, N. (1989). Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO Journal 8, 3867-74.
148. Allen, M. I., Deslauriers, M., Andrews, C. W., Tipples, G. A., Walters K.-A., Tyrrell, D. L. J. et al. (1998). Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27, 1670-7.
149. Fischer, K. P. & Tyrrell, D. L. (1996). Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2′, 3′-dideoxy-3′-thiacytidine] in vitro. Antimicrobial Agents and Chemotherapy 40, 1957-60.
150. Chayama, K., Suzuki, Y., Kobayashi, M., Kobayashi, A., Tsubota, A. & Hashimoto, M. (1998). Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27, 1711-6.
151. Honkoop, P., Niesters, H. G., de Man, R. A., Osterhaus, A. D. & Schalm, S. W. (1997). Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. Journal of Hepatology 26, 1393-5.
152. Ling, R., Mutimer, D., Ahmed, M., Boxall, E. H., Elias, E., Dusheiko, G. M. et al. (1996). Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24, 711-3.
153. Tipples, G. A., Ma, M. M., Fischer, K. P., Bain, V. G., Kneteman, N. M. & Trell, D. L. (1996). Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24, 714-7.
154. Niesters, H. G., Honkoop, P., Haagsma, E. B., de Man, R. A., Schalm, S. W. & Osterhaus, A. D. (1998). Identification of more than one mutation in the hepatitis B virus polymerase arising during prolonged lamivudine treatment. Journal of Infectious Diseases 177, 1382-5.
155. Stuyver, L. J., Locarnini, S. A., Lok, A., Richman, D. D., Carman, W. F., Dienstag, J. L. et al. (2001). Nomenclature for anti-viral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33, 751-7.
156. Aye, T. T., Bartholomeusz, A., Shaw, T., Bowden, S., Breschkin, A., McMillan, J. et al. (1997). Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. Journal of Hepatology 26, 1148-53.
157. Tillmann, H. L., Trautwein, C., Bock, T., Boker, K. H., Jackel, E., Glowienka, M. et al. (1999). Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 30, 244-56.
158. Yeh, C. T., Chien, R. N., Chu, C. M. & Liaw, Y. F. (2000). Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31, 1318-26.
159. Niesters, H. G. M., De-Man, R. A., Pas, S. D., Fries, E. & Osterhaus, A. D. (2002). Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. Journal of Medical Microbiology 51, 695-9.
160. Jaeger, J., Restle, T. & Steitz, T. A. (1998). The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor. EMBO Journal 17, 4535-42.
161. Das, K., Xiong, X., Yang, H., Westland, C. E., Gibbs, C. S., Sarafianos, S. G. et al. (2001). Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). Journal of Virology 75, 4771-9.
162. Melegari, M., Scaglioni, P. P. & Wands, J. R. (1998). Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27, 628-33.
163. Ono, S. K., Kato, N., Shiratori, Y., Kato, J., Goto, T., Schinazi, R. F. et al. (2001). The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. Journal of Clinical Investigation 107, 449-55.
164. Bock, C. T., Tillmann, H. L., Torresi, J., Klempnauer, J., Locarnini, S., Manns, M. P. et al. (2002). Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122, 264-73.
165. Torresi, J., Earnest-Silveira, L., Civitico, G., Walters, T., Lewin, S., Fyfe, J. et al. (2002). Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the 'Fingers' subdomain of the viral polymerase selected as a consequence of mutations in the overlapping s gene. Virology 299, 88-99.
166. Xiong, X., Flores, C., Yang, H., Toole, J. J. & Gibbs, C. S. (1998). Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28, 1669-73.
167. Perrillo, R., Schiff, E., Yoshida, E., Statler, A., Hirsch, K., Wright, T. et al. (2000). Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32, 129-34.
168. Ono-Nita, S. K., Kato, N., Shiratori, Y., Masaki, T., Lan, K. H., Carrilho, F. J. et al. (1999). YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29, 939-45.
169. Chin, R., Shaw, T., Torresi, J., Sozzi, V., Trautwein, C. & Bock, T. (2001). In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrobial Agents and Chemotherapy 45, 2495-501.
170. Seigneres, B., Pichoud, C., Martin, P., Furman, P., Trepo, C. & Zoulim, F. (2002). Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36, 710-22.
171. Ying, C., De Clercq, E., Nicholson, W., Furman, P. & Neyts, J. (2000). Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. Journal of Viral Hepatitis 7, 161-5.
172. Yamamoto, T., Litwin, S., Zhou, T., Zhu, Y., Condreay, L., Furman, P. et al. (2002). Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Journal of Virology 76, 1213-23.
173. Shaw, T., Mok, S. S. & Locarnini, S. A. (1996). Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 24, 996-1002.
174. Shaw, T., Amor, P., Civitico, G., Boyd, M. & Locarnini, S. (1994). In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrobial Agents and Chemotherapy 38, 719-23.
175. Dannaoui, E., Trepo, C. & Zoulim, F. (1997). Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antimicrobial Agents and Chemotherapy 8, 38-46.
176. Lin, E., Luscombe, C., Colledge, D., Wang, Y. & Locarnini, S. (1998). Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrobial Agents and Chemotherapy 42, 2132-7.
177. Tsiquaye, K., Slomka, M. & Maung, M. (1994). Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. Journal of Medical Virology 42, 306-10.
178. Tsiquaye, K., Sutton, D., Maung, M. & Boyd, M. (1996). Antiviral activities and pharmacokinetics of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis B virus. Antiviral Chemistry and Chemotherapy 7, 153-9.
179. Main, J., Brown, J., Howells, C., Galassini, R., Crossey, M., Karayiannis, P. et al. (1996). A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis 3, 211-5.
180. Trepo, C., Jezek, P., Atkinson, G., Boon, R. & Young, C. (2000). Famciclovir in chronic hepatitis B: results of a dose-finding study. Journal of Hepatology 32, 1011-8.
181. de Man, R. A., Marcellin, P., Habal, F., Desmond, P., Wright, T., Rose, T. et al. (2000). A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 32, 413-7.
182. Benner, K., Rosen, H. & Flora, K. (1996). Famciclovir treatment of decompensated HBV cirrhosis. Hepatology 24, A622.
183. Kruger, M., Tillmann, H. L., Trautwein, C., Bode, U., Oldhafer, K. & Maschek, H. (1996). Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transplant Surgery 2, 253-62.
184. Neuhaus, P., Manns, M. & Atkinson, G. (1997). Safety and efficacy of famciclovir for the treatment of recurrent hepatitis B in liver transplant recipients [abstract]. Hepatology 26, 528A.
185. Manns, M. P., Neuhaus, P., Atkinson, G. F., Griffin, K. E., Barnass, S., Vollmar, J. et al. (2001). Famciclovir Liver Transplant Study Group. Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study. Transplant Infectious Disease 3, 16-23.
186. Bartholmeusz, A., Schinazi, R. F. & Locarnini, S. A. (1998). Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hepatitis Reviews 3, 167-87.
187. Seigneres, B., Pichoud, C., Ahmed, S. S., Hantz, O., Trepo, C. & Zoulim, F. (2000). Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. Journal of Infectious Diseases 181, 1221-33.
188. Gunther, S., von Breunig, F., Santantonio, T., Jung, M. C., Gaeta, G. B., Fischer, L. et al. (1999). Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. Journal of Hepatology 30, 749-54.
189. Pichoud, C., Seigneres, B., Wang, Z., Trepo, C. & Zoulim, F. (1999). Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 29, 230-7.
190. Xiong, X., Yang, H., Westland, C. E., Zou, R. & Gibbs, C. S. (2000). In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 31, 219-24.
191. Calio, R., Villani, N., Balestra, E., Sesa, F., Holy, A., Balzarini, J. et al. (1994). Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Research 23, 77-89.
192. Heijtink, R. A., De Wilde, G. A., Kruining, J., Berk, L., Balzarini, J., De Clercq, E. et al. (1993). Inhibitory effect of 9-(2-phosphonyl-methoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Research 21, 141-53.
193. Nicoll, A. J., Colledge, D. L., Toole, J. J., Angus, P. W., Smallwood, R. A. & Locarnini, S. A. (1998). Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue. Antimicrobial Agents and Chemotherapy 42, 3130-5.
194. Gilson, R. J., Chopra, K. B., Newell, A. M., Murray-Lyon, I. M., Nelson, M. R., Rice, S. J. et al. (1999). A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis 6, 387-95.
195. Tsiang, M., Rooney, J. F., Toole, J. J. & Gibbs, C. (1999). Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29, 1863-9.
196. Peters, M. G., Singer, G., Howard, T., Jacobsmeyer, S., Xiong, X., Gibbs, C. S. et al. (1999). Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 68, 1912-4.
197. Cullen, J. M., Li, D. H., Brown, C., Eisenberg, E. J., Cundy, K. C., Wolfe, J. et al. (2001). Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrobial Agents and Chemotherapy 45, 2740-5.
198. Benhamou, Y., Bochet, M., Thibault, V., Calvez, V., Fievet, M. H., Vig, P. et al. (2001). Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 358, 718-23.
199. Mutimer, D., Feraz-Neto, B. H., Harrison, R., O'Donnell, K., Shaw, J., Cane, P. et al. (2001). Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 49, 860-3.
200. Walsh, K. M., Woodall, T., Lamy, P., Wight, D. G., Bloor, S. & Alexander, G. J. (2001). Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 49, 436-40.
201. Yang, H., Westkand, C. E., Delaney, W. E., Heathcote, E. J., Ho, V., Fry. J. et al. (2002). Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 36, 464-73.
202. Deeks, S. G., Collier, A., Lalezari, J., Pavia, A., Rodrigue, D., Drew, W. L. et al. (1997). The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. Journal of Infectious Diseases 176, 1517-23.
203. Dandri, M., Burda, M., Will, H. & Petersen, J. (2000). Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 32, 139-46.
204. Delmas, J., Schorr, O., Jamard, C., Gibbs, C., Trepo, C., Hantz, O. et al. (2002). Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrobial Agents and Chemotherapy 46, 425-33.
205. Seifer, M., Hamatake, R. K., Colonno, R. J. & Standring, D. N. (1998). In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrobial Agents and Chemotherapy 42, 3200-8.
206. Genovesi, E. V., Lamb, L., Medina, I., Taylor, D., Seifer, M., Innaimo, S. et al. (1998). Efficacy of the carbocyclic 2′-deoxy-guanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrobial Agents and Chemotherapy 42, 3209-17.
207. Innaimo, S. F., Seifer, M., Bisacchi, G. S., Standring, D. N., Zahler, R. & Colonno, R. J. (1997). Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrobial Agents and Chemotherapy 41, 1444-8.
208. Marion, P. L., Salazar, F. H., Winters, M. A. & Colonno, R. J. (2002). Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrobial Agents and Chemotherapy 46, 82-8.
209. Colonno, R. J., Genovesi, E. V., Medina, I., Lamb, L., Durham, S. K., Huang, M. L. et al. (2001). Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. Journal of Infectious Diseases 184, 1236-45.
210. Lai, C. L., Rosmawati, M., Lao, J., Van Vlierberghe, H., Anderson, F. H., Thomas, N. et al. (2002). Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123, 1831-8.
211. Levine, S., Hernandez, D., Yamanaka, G., Zhang, S., Rose, R., Weinheimer, S. et al. (2002). Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrobial Agents and Chemotherapy 46, 2525-32.
212. de Man, R. A., Wolters, L. M., Nevens, F., Chua, D., Sherman, M., Lai, C. L. et al. (2001). Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 34, 578-82.
213. Furman, P. A., Davis, M., Liotta, D. C., Paff, M., Frick, L. W., Nelson, D. J. et al. (1992). The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrobial Agents and Chemotherapy 36, 2686-92.
214. Feng, Y., Kong, Y. Y., Wang, Y. & Qi, G. R. (2001). Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly(A) signal sequence in cultured cells. Biological Chemistry 382, 655-60.
215. Condreay, L., Condreay, J., Jansen, R., Paff, M. & Averett, D. (1996). (-)-cis-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes. Antimicrobial Agents and Chemotherapy 40, 520-3.
216. Condreay, L., Jansen, R., Powdrill, T., Johnson, L., Selleseth, D., Paff, M. et al. (1994). Evaluation of the potent anti-HBV agent (-)cis-5-fluoro-1(2-(hydroxymethyl)-1,3-oxathiolan-5-yl) cytosine in a novel in vivo model. Antimicrobial Agents and Chemotherapy 38, 616-9.
217. Korba, B. E., Schinazi, R. F., Cote, P., Tennant, B. C. & Gerin, J. L. (2000). Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrobial Agents and Chemotherapy 44, 1757-60.
218. Cullen, J. M., Smith, S. L., Davis, M. G., Dunn, S. E., Botteron, C., Cecchi, A. et al. (1997). In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl) cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrobial Agents and Chemotherapy 41, 2076-82.
219. Gish, R. G., Leung, N. W., Wright, T. L., Trinh, H., Lang, W., Kessler, H. A. et al. (2002). Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrobial Agents and Chemotherapy 46, 1734-40.
220. Ladner, S. K., Miller, T. J., Otto, M. J. & King, R. W. (1998). The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antiviral Chemistry and Chemotherapy 9, 65-72.
221. Fischer, K. P. & Tyrrell, D. L. (1996). Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2′, 3′-dideoxy-3′-thiacytidine] in vitro. Antimicrobial Agents and Chemotherapy 40, 1957-60.
222. Angus, P., Richards, M., Bowden, S., Ireton, J., Sinclair, R., Jones, R. et al. (1993). Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. Journal of Gastroenterology and Hepatology 8, 353-7.
223. Gish, R. G., Lau, J. Y., Brooks, L., Fang, J. W., Steady, S. L., Imperial, J. C. et al. (1996). Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 23, 1-7.
224. Hadziyannis, S. J., Manesis, E. K. & Papakonstantinou, A. (1999). Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study. Journal of Hepatology 31, 210-4.
225. Luscombe, C., Pedersen, J., Bowden, S. & Locarnini, S. (1994). Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy. Liver 14, 182-92.
226. Luscombe, C., Pedersen, J., Uren, E. & Locarnini, S. (1996). Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression. Hepatology 24, 766-73.
227. Statschke, K., Colacino, J., Mabry, T. & Jones, C. (1994). The in vitro anti-hepatitis B virus activity of FIAU [1-(2′-deoxy-2′fluoro-1-[beta]-D-arabinofuranosyl-5-iodo) uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Research 23, 45-61.
228. Lewis, W., Meyer, R. R., Simpson, J. F., Colacino, J. M. & Perrino, F. W. (1994). Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate. Biochemistry 33, 14620-4.
229. Cui, L., Yoon, S., Schinazi, R. F. & Sommadossi, J. P. (1995). Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. Journal of Clinical Investigation 95, 555-63.
230. McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y. et al. (1995). Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine 333, 1099-105.
231. Genovesi, E. V., Lamb, L., Medina, I., Taylor, D., Seifer, M., Innaimo, S. et al. (2000). Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatitis B virus (HBV) infection. Antiviral Research 48, 197-203.
232. Zoulim, F., Dannaoui, E., Borel, C., Hantz, O., Lin, T. S., Liu, S. H. et al. (1996). 2′,3′-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrobial Agents and Chemotherapy 40, 448-53.
233. Aguesse-Germon, S., Liu, S. H., Chevallier, M., Pichoud, C., Jamard, C., Borel, C. et al. (1998). Inhibitory effect of 2′-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. Antimicrobial Agents and Chemotherapy 42, 369-76.
234. Peek, S. F., Cote, P. J., Jacob, J. R., Toshkov, I. A., Hornbuckle, W. E., Baldwin, B. H. et al. (2001). Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 33, 254-66.
235. Le Guerhier, F., Pichoud, C., Jamard, C., Guerret, S., Chevallier, M., Peyrol, S. et al. (2001). Antiviral activity of β-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrobial Agents and Chemotherapy 45, 1065-77.
236. Kamiya, N., Kubota, A., Iwase, Y., Sekiya, K., Ubasawa, M. & Yuasa, S. (2002). Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus. Antimicrobial Agents and Chemotherapy 46, 2872-7.
237. Ono-Nita, S. K., Kato, N., Shiratori, Y., Carrilho, F. J. & Omata, M. (2002). Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrobial Agents and Chemotherapy 46, 2602-5.
238. Bryant, M. L., Bridges, E. G., Placidi, L., Faraj, A., Loi, A. G., Pierra, C. et al. (2001). Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrobial Agents and Chemotherapy 45, 229-35.
239. Standring, D. N., Bridges, E. G., Placidi, L., Faraj, A., Loi, A. G., Pierra, C. et al. (2001). Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antiviral Chemistry and Chemotherapy 12, Suppl. 1, 119-29.
240. Hernandez-Santiago, B., Placidi, L., Cretton-Scott, E., Faraj, A., Bridges, E. G., Bryant, M. L. et al. (2002). Pharmacology of beta-L-thymidine and beta-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrobial Agents and Chemotherapy 46, 1728-33.
241. Nelson, M., Portsmouth, S., Stebbing, J., Atkins, M., Barr, A., Matthews, G. et al. (2003). An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 17, F7-F10.
242. Ristig, M. B., Crippin, J., Aberg, J. A., Powderly, W. G., Lisker Melman, M., Kessels, L. et al. (2002). Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. Journal of Infectious Diseases 186, 1844-7.
243. van Bommel, F., Wunsche, T., Schurmann, D. & Berg, T. (2002). Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 36, 507-8.
244. Barbaro, G., Zechini, F., Pellicelli, A. M., Francavilla, R., Scotto, G., Bacca, D. et al. (2001). Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. Journal of Hepatology 35, 406-11.
245. Korba, B. E., Cote, P., Hombuckle, W., Schinazi, R., Gangemi, J. D., Tennant, B. C. et al. (2000). Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks. Antiviral Therapy 5, 95-104.
246. Mutimer, D., Naoumov, N., Honkoop, P., Marinos, G., Ahmed, M., de Man, R. et al. (1998). Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. Journal of Hepatology 28, 923-9.
247. Marques, A. R., Lau, D. T., McKenzie, R., Straus, S. E. & Hoofnagle, J. H. (1998). Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B. Journal of Infectious Diseases 178, 1483-7.
248. Lau, G. K., Tsiang, M., Hou, J., Yuen, S., Carman, W. F., Zhang, L. et al. (2000). Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 32, 394-9.
249. Colledge, D., Locarnini, S. & Shaw, T. (1997). Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 26, 216-25.
250. Korba, B. E., Cote, P., Hornbuckle, W., Schinazi, R., Gerin, J. L. & Tennant, B. C. (2000). Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks. Antiviral Research 45, 19-32.
251. Colledge, D., Civitico, G., Locarnini, S. & Shaw, T. (2000). In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrobial Agents and Chemotherapy 44, 551-60.
252. Sangfelt, P., Uhnoo, I., Hollander, A., Lindh, G. & Weiland, O. (2002). Lamivudine and famciclovir combination therapy with or without addition of interferon-alpha-2b for HBeAg-positive chronic hepatitis B: a pilot study. Scandinavian Journal of Infectious Diseases 34, 505-11.
253. Akbar, S. M., Kajino, K., Tanimoto, K., Kurose, K., Masumoto, T., Michitaka, K. et al. (1997). Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice. Journal of Hepatology 26, 131-7.
254. Mancini, M., Hadchouel, M., Tiollais, P., Pourcel, C. & Michel, M. L. (1993). Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing 'nonresponse'to HBsAg. Journal of Medical Virology 39, 67-74.
255. Pol, S., Driss, F., Michel, M. L., Nalpas, B., Berthelot, P. & Brechot, C. (1994). Specific vaccine therapy in chronic hepatitis B infection. Lancet 344, 342.
256. Wen, Y. M., Wu, X. H., Hu, D. C., Zhang, Q. P. & Guo, S. Q. (1995). Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 345, 1575-6.
257. Pol, S., Nalpas, B., Driss, F., Michel, M. L., Tiollais, P., Denis, J. et al. (2001). Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. Journal of Hepatology 34, 917-21.
258. Heineman, T. C., Clements-Mann, M. L., Poland, G. A., Jacobson, R. M., Izu, A. E., Sakamoto, D. et al. (1999). A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17, 2769-78.
259. Wright, T. L., Tong, M. J. & Hsu, H. H. (1999). Phase 1 study of a potent adjuvanted hepatitis B vaccine (HBV/MF59) for therapy of chronic hepatitis. Hepatology 30, 421A.
260. Davis, H. L. (2000). Use of CpG for enhancing specific immune responses. Current Topics in Microbiology and Immunology 247, 171-83.
261. Malanchere-Bres, E., Payette, P. J., Mancini, M., Tiollais, P., Davis, H. L. & Michel, M. L. (2001). CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. Journal of Virology 75, 6482-91.
262. Davis, H. L., Suparto, I. I., Weeratna, R. R., Jumintarto, Iskandriati, D. D., Chamzah, S. S. et al. (2000). CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18, 1920-4.
263. Heathcote, J., McHutchison, J., Lee, S., Tong, M., Benner, K., Minuk, G. et al. (1999). A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 30, 531-6.
264. Hervas-Stubbs, S., Lasarte, J. J., Sarobe, P., Prieto, J., Cullen, J., Roggendorf, M. et al. (1997). Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. Journal of Hepatology 27, 726-37.
265. Davis, H. L., Michel, M. L. & Whalen, R. G. (1993). DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Human Molecular Genetics 2, 1847-51.
266. Michel, M. L., Davis, H. L., Schleef, M., Mancini, M., Tiollais, P. & Whalen, R. G. (1995). DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proceedings of the National Academy of Sciences, USA 92, 5307-11.
267. Mancini, M., Hadchouel, M., Davis, H. L., Whalen, R. G., Tiollais, P. & Michel, M. L. (1996). DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proceedings of the National Academy of Sciences, USA 93, 12496-501.
268. Oka, Y., Akbar, S. M., Horiike, N., Joko, K. & Onji, M. (2001). Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice. Immunology 103, 90-7.
269. Mancini, M., Hadchouel, M., Tiollais, P. & Michel, M. L. (1998). Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization. Journal of Immunology 161, 5564-70.
270. Ishioka, G. Y., Fikes, J., Hermanson, G., Livingston, B., Crimi, C., Qin, M. et al. (1999). Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. Journal of Immunology 162, 3915-25.
271. Chow, Y. H., Huang, W. L., Chi, W. K., Chu, Y. D. & Tao, M. H. (1997). Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. Journal of Virology 71, 169-78.
272. Triyatni, M., Jilbert, A. R., Qiao, M., Miller, D. S. & Burrell, C. J. (1998). Protective efficacy of DNA vaccines against duck hepatitis B virus infection. Journal of Virology 72, 84-94.
273. Rollier, C., Sunyach, C., Barraud, L., Madani, N., Jamard, C., Trepo, C. et al. (1999). Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 116, 658-65.
274. Davis, H. L., McCluskie, M. J., Gerin, J. L. & Purcell, R. H. (1996). DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proceedings of the National Academy of Sciences, USA 93, 7213-8.
275. Gramzinski, R. A., Millan, C. L., Obaldia, N., Hoffman, S. L. & Davis, H. L. (1998). Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Molecular Medicine 4, 109-18.
276. Prince, A. M., Whalen, R. & Brotman, B. (1997). Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine 15, 916-9.
277. Pancholi, P., Lee, D. H., Liu, Q., Tackney, C., Taylor, P., Perkus, M. et al. (2001). DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33, 448-54.
278. Sallberg, M., Hughes, J., Javadian, A., Ronlov, G., Hultgren, C., Townsend, K. et al. (1998). Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Human Gene Therapy 9, 1719-29.
279. Roy, M. J., Wu, M. S., Barr, L. J., Fuller, J. T., Tussey, L. G., Speller, S. et al. (2000). Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19, 764-78.
280. Wagner, R. W. (1994). Gene inhibition using antisense oligodeoxynucleotides. Nature 372, 333-5.
281. Stein, C. A. & Cohen, J. S. (1988). Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Research 48, 2659-68.
282. Blum, H. E., Galun, E., von Weizsacker, F. & Wands, J. R. (1991). Inhibition of hepatitis B virus by antisense oligodeoxynucleotides. Lancet 337, 1230.
283. Yao, Z. Q., Zhou, Y. X., Wang, A. L., Bai, X. F. & Yang, W. S. (1995). Inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Journal of Viral Hepatitis 2, 85-9.
284. Korba, B. E. & Gerin, J. L. (1995). Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. Antiviral Research 28, 225-42.
285. Nakazono, K., Ito, Y., Wu, C. H. & Wu, G. Y. (1996). Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology 23, 1297-303.
286. Moriya, K., Matsukura, M., Kurokawa, K. & Koike, K. (1996). In vivo inhibition of hepatitis B virus gene expression by antisense phosphorothioate oligonucleotides. Biochemical and Biophysical Research Communications 218, 217-23.
287. Madon, J. & Blum, H. E. (1996). Receptor-mediated delivery of hepatitis B virus DNA and antisense oligodeoxynucleotides to avian liver cells. Hepatology 24, 474-81.
288. Offensperger, W. B., Offensperger, S. & Blum, H. E. (1998). Antisense therapy of hepatitis B virus infection. Molecular Biotechnology 9, 161-70.
289. Soni, P. N., Brown, D., Saffie, R., Savage, K., Moore, D., Gregoriadis, G. et al. (1998). Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Hepatology 28, 1402-10.
290. Robaczewska, M., Guerret, S., Remy, J. S., Chemin, I., Offensperger, W. B., Chevallier, M. et al. (2001). Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver. Gene Therapy 8, 874-81.
291. Fedor, M. J. (2000). Structure and function of the hairpin ribozyme. Journal of Molecular Biology 297, 269-91.
292. von Weizsacker, F., Blum, H. E. & Wands, J. R. (1992). Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template. Biochemical and Biophysical Research Communications 189, 743-8.
293. Beck, J. & Nassal, M. (1995). Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Research 23, 4954-62.
294. Welch, P. J., Tritz, R., Yei, S., Barber, J. & Yu, M. (1997). Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Therapy 4, 736-43.
295. zu Putlitz, J., Yu, Q., Burke, J. M. & Wands, J. R. (1999). Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. Journal of Virology 73, 5381-7.
296. Kim, Y. K., Junn, E., Park, I., Lee, Y., Kang, C. & Ahn, J. K. (1999). Repression of hepatitis B virus X gene expression by hammerhead ribozymes. Biochemical and Biophysical Research Communications 257, 759-65.
297. Passman, M., Weinberg, M., Kew, M. & Arbuthnot, P. (2000). In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochemical and Biophysical Research Communications 268, 728-33.
298. Weinberg, M., Passman, M., Kew, M. & Arbuthnot, P. (2000). Hammerhead ribozyme-mediated inhibition of hepatitis B virus X gene expression in cultured cells. Journal of Hepatology 33, 142-51.
299. Scaglioni, P., Melegari, M., Takahashi, M., Chowdhury, J. R. & Wands, J. (1996). Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 24, 1010-7.
300. Butz, K., Denk, C., Fitscher, B., Crnkovic-Mertens, I., Ullmann, A., Schroder, C. H. et al. (2001). Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 20, 6579-86.